SCHEMBL10345940

SCHEMBL10345940

C=C1C=Cc2cncnc2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776601 0.65
SCHEMBL29916509 0.64
SCHEMBL17080992 0.64
SCHEMBL11264321 0.63
SCHEMBL5868568 0.62
SCHEMBL13833236 0.58 CDC25B (0.34)
SCHEMBL15326918 0.57
SCHEMBL23440004 0.56
SCHEMBL29541154 0.56
SCHEMBL27432695 0.55 HTT (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174652-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-06-22 US disclosed
US-9434700-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION 2016-09-06 US disclosed
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 US disclosed
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA AFRAXIS HOLDINGS INC (US) 2014-12-11 US disclosed
US-20120184547-A1 METHODS FOR TREATING SCHIZOPHRENIA AFRAXIS, INC. (US) 2012-07-19 US disclosed